Hasan Abdul-Karim of the Marion Star writes that the Ohio State University is looking for people with mild-to-moderate Alzheimer’s disease to participate in a national clinical research study. The purpose is to evaluate the effects of a drug that may improve memory.
The university will be one of approximately 40 research sites across the country testing troriluzole. The phase two study, called T2 Protect AD, will see if the drug can slow down thinking problems associated with the neurological disease.
Ashley Garcia, a clinical research coordinator at OSU, said they are looking to recruit at least 10 people for the study. She said participants must have already been diagnosed with the disease and are between 50 to 85-years-old.
The trial will last for almost a year and participants will be asked to take a pill once a day. They will also be required to visit researchers on OSU’s Columbus campus once a month. Assessments will be done testing memory and thinking.
Garcia said they are hoping the drug will make a difference in slowing the progression of the illness.
She said OSU is one of two research sites for the study in Ohio. The other is at Case Western Reserve University in Cleveland.
The study is sponsored by New Haven-based Biohaven Pharmaceutical Holding Company Ltd., and is coordinated by the Alzheimer’s Disease Cooperative Study (ADCS) based at the University of California, San Diego.
Troriluzole modulates the chemical compound glutamate, protecting against neuron loss. Glutamate problems in the brain can lead to brain cell dysfunction, which can contribute to Alzheimer’s disease, according to Dr. Howard Feldman, the director of the ADCS.
An estimated 5.7 million people in the United States suffer from mild-to-moderate Alzheimer’s Disease, with those numbers expected to triple by 2050 without prevention or cure, according to the cooperative.
Feldman said researchers are looking at the effects of the drug on patients who are already being treated with Alzheimer’s medications, for at least three months.
The medication being tested is similar to riluzole, a drug first approved by the Federal Drug Administration in 1995 to slightly slow disease progression in patients with Amyotrophic Lateral Sclerosis (ALS).
Researchers hope that Troriluzole will have a positive effect on those with Alzheimer’s, slowing down the the cogitative decline associated with the illness.
Those interested in participating in the study at Ohio State University can call 614- 293-4969 or visit www.t2protect.org. They can also contact Garcia at 614-293-5183.